share_log

ShockWave Medical Analyst Ratings

ShockWave Medical Analyst Ratings

冲击波医学分析师评级
Benzinga Analyst Ratings ·  2023/01/26 06:46
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/26/2023 46.94% Piper Sandler $300 → $280 Maintains Overweight
01/06/2023 17.55% Morgan Stanley $290 → $224 Maintains Equal-Weight
12/12/2022 23.33% Wells Fargo → $235 Downgrades Overweight → Equal-Weight
11/08/2022 57.44% Wells Fargo $255 → $300 Maintains Overweight
10/11/2022 52.19% Morgan Stanley $255 → $290 Maintains Equal-Weight
09/06/2022 -13.41% Oppenheimer → $165 Downgrades Perform → Underperform
08/29/2022 77.38% Piper Sandler $278 → $338 Maintains Overweight
08/09/2022 33.82% Morgan Stanley $201 → $255 Maintains Equal-Weight
08/09/2022 33.82% Wells Fargo $176 → $255 Maintains Overweight
08/09/2022 45.89% Piper Sandler $245 → $278 Maintains Overweight
07/15/2022 5.48% Morgan Stanley $180 → $201 Maintains Equal-Weight
05/10/2022 -5.54% Morgan Stanley $199 → $180 Maintains Equal-Weight
05/10/2022 -7.64% Wells Fargo $235 → $176 Maintains Overweight
05/10/2022 -8.16% SVB Leerink $250 → $175 Maintains Outperform
04/06/2022 33.82% Wolfe Research → $255 Initiates Coverage On → Outperform
02/18/2022 4.43% Morgan Stanley $210 → $199 Maintains Equal-Weight
02/18/2022 -0.29% SVB Leerink $160 → $190 Maintains Outperform
01/07/2022 10.21% Morgan Stanley $204 → $210 Maintains Equal-Weight
12/06/2021 23.33% Wells Fargo → $235 Upgrades Equal-Weight → Overweight
11/09/2021 23.33% Wells Fargo $200 → $235 Maintains Equal-Weight
11/09/2021 39.07% SVB Leerink $250 → $265 Maintains Outperform
08/10/2021 4.96% Morgan Stanley $152 → $200 Maintains Equal-Weight
08/10/2021 15.46% SVB Leerink $208 → $220 Maintains Outperform
07/15/2021 9.16% SVB Leerink → $208 Initiates Coverage On → Outperform
07/12/2021 4.96% B of A Securities $180 → $200 Downgrades Buy → Neutral
06/18/2021 -0.81% Wells Fargo → $189 Downgrades Overweight → Equal-Weight
06/07/2021 -0.81% Wells Fargo $161 → $189 Maintains Overweight
05/11/2021 6.01% Canaccord Genuity $149 → $202 Maintains Buy
05/11/2021 -20.23% Morgan Stanley $145 → $152 Maintains Equal-Weight
05/11/2021 -15.51% Wells Fargo $151 → $161 Maintains Overweight
05/11/2021 -5.54% B of A Securities → $180 Upgrades Neutral → Buy
04/19/2021 -23.9% Morgan Stanley $130 → $145 Maintains Equal-Weight
03/31/2021 -21.81% Canaccord Genuity $147 → $149 Maintains Buy
02/22/2021 -31.78% Morgan Stanley $103 → $130 Maintains Equal-Weight
02/19/2021 -31.78% Morgan Stanley $103 → $130 Maintains Equal-Weight
02/18/2021 -29.68% Piper Sandler $132 → $134 Maintains Neutral
02/02/2021 -31.25% Canaccord Genuity $87 → $131 Maintains Buy
01/20/2021 -30.73% Piper Sandler $96 → $132 Downgrades Overweight → Neutral
12/15/2020 -45.95% Morgan Stanley $89 → $103 Maintains Equal-Weight
11/11/2020 -53.29% Morgan Stanley $72 → $89 Maintains Equal-Weight
10/19/2020 -62.21% Morgan Stanley $55 → $72 Maintains Equal-Weight
10/16/2020 -52.77% Wells Fargo $80 → $90 Maintains Overweight
08/12/2020 -69.56% Piper Sandler $54 → $58 Maintains Overweight
08/12/2020 -71.14% Morgan Stanley $42 → $55 Maintains Equal-Weight
06/11/2020 — Oppenheimer Upgrades Underperform → Perform
06/09/2020 -72.19% Canaccord Genuity $46 → $53 Maintains Buy
05/13/2020 -77.96% Morgan Stanley $40 → $42 Maintains Equal-Weight
05/13/2020 -75.86% Wells Fargo $43 → $46 Maintains Overweight
04/01/2020 -87.93% Oppenheimer → $23 Downgrades Perform → Underperform
03/27/2020 -79.01% Morgan Stanley $51 → $40 Maintains Equal-Weight
12/17/2019 -75.33% Morgan Stanley $35 → $47 Maintains Equal-Weight
12/12/2019 — Wells Fargo Upgrades Equal-Weight → Overweight
11/08/2019 -81.63% Morgan Stanley $32 → $35 Maintains Equal-Weight
10/22/2019 — Oppenheimer Initiates Coverage On → Perform
10/21/2019 -79.53% Piper Sandler → $39 Initiates Coverage On → Overweight
04/01/2019 -82.68% Wells Fargo → $33 Initiates Coverage On → Market Perform
04/01/2019 — Morgan Stanley Initiates Coverage On → Equal-Weight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/26/2023 46.94% 派珀·桑德勒 $300 → $280 維護 超重
01/06/2023 17.55% 摩根士丹利 $290 → $224 維護 等重
12/12/2022 23.33% 富國銀行 → $235 評級下調 超重→等重
11/08/2022 57.44% 富國銀行 $255 → $300 維護 超重
10/11/2022 52.19% 摩根士丹利 $255 → $290 維護 等重
09/06/2022 -13.41% 奧本海默 → $165 評級下調 執行→未充分執行
08/29/2022 77.38% 派珀·桑德勒 $278 → $338 維護 超重
08/09/2022 33.82% 摩根士丹利 $201 → $255 維護 等重
08/09/2022 33.82% 富國銀行 $176 → $255 維護 超重
08/09/2022 45.89% 派珀·桑德勒 $245 → $278 維護 超重
07/15/2022 5.48% 摩根士丹利 $180 → $201 維護 等重
05/10/2022 -5.54% 摩根士丹利 $199 → $180 維護 等重
05/10/2022 -7.64% 富國銀行 $235 → $176 維護 超重
05/10/2022 -8.16% SVB Leerink $250 → $175 維護 跑贏大盤
04/06/2022 33.82% 沃爾夫研究 → $255 開始承保 →跑贏大盤
02/18/2022 4.43% 摩根士丹利 $210 → $199 維護 等重
02/18/2022 -0.29% SVB Leerink $160 → $190 維護 跑贏大盤
01/07/2022 10.21% 摩根士丹利 $204 → $210 維護 等重
12/06/2021 23.33% 富國銀行 → $235 升級 等重→超重
11/09/2021 23.33% 富國銀行 $200 → $235 維護 等重
11/09/2021 39.07% SVB Leerink $250 → $265 維護 跑贏大盤
08/10/2021 4.96% 摩根士丹利 $152 → $200 維護 等重
08/10/2021 15.46% SVB Leerink $208 → $220 維護 跑贏大盤
07/15/2021 9.16% SVB Leerink → $208 開始承保 →跑贏大盤
07/12/2021 4.96% B of A證券 $180 → $200 評級下調 購買→中性
06/18/2021 -0.81% 富國銀行 → $189 評級下調 超重→等重
06/07/2021 -0.81% 富國銀行 $161 → $189 維護 超重
05/11/2021 6.01% 卡納科特·格納奇 $149 → $202 維護 買
05/11/2021 -20.23% 摩根士丹利 $145 → $152 維護 等重
05/11/2021 -15.51% 富國銀行 $151 → $161 維護 超重
05/11/2021 -5.54% B of A證券 → $180 升級 中性→購買
04/19/2021 -23.9% 摩根士丹利 $130 → $145 維護 等重
03/31/2021 -21.81% 卡納科特·格納奇 $147 → $149 維護 買
02/22/2021 -31.78% 摩根士丹利 $103 → $130 維護 等重
02/19/2021 -31.78% 摩根士丹利 $103 → $130 維護 等重
02/18/2021 -29.68% 派珀·桑德勒 $132 → $134 維護 中性
02/02/2021 -31.25% 卡納科特·格納奇 $87 → $131 維護 買
01/20/2021 -30.73% 派珀·桑德勒 $96 → $132 評級下調 超重→中性
12/15/2020 -45.95% 摩根士丹利 $89 → $103 維護 等重
11/11/2020 -53.29% 摩根士丹利 $72 → $89 維護 等重
10/19/2020 -62.21% 摩根士丹利 $55 → $72 維護 等重
10/16/2020 -52.77% 富國銀行 $80 → $90 維護 超重
08/12/2020 -69.56% 派珀·桑德勒 $54 → $58 維護 超重
08/12/2020 -71.14% 摩根士丹利 $42 → $55 維護 等重
06/11/2020 — 奧本海默 升級 表現遜於→表現
06/09/2020 -72.19% 卡納科特·格納奇 $46 → $53 維護 買
05/13/2020 -77.96% 摩根士丹利 $40 → $42 維護 等重
05/13/2020 -75.86% 富國銀行 $43 → $46 維護 超重
04/01/2020 -87.93% 奧本海默 → $23 評級下調 執行→未充分執行
03/27/2020 -79.01% 摩根士丹利 $51 → $40 維護 等重
12/17/2019 -75.33% 摩根士丹利 $35 → $47 維護 等重
12/12/2019 — 富國銀行 升級 等重→超重
11/08/2019 -81.63% 摩根士丹利 $32 → $35 維護 等重
10/22/2019 — 奧本海默 開始承保 →性能
10/21/2019 -79.53% 派珀·桑德勒 → $39 開始承保 →超重
04/01/2019 -82.68% 富國銀行 → $33 開始承保 →市場表現
04/01/2019 — 摩根士丹利 開始承保 →等重

What is the target price for ShockWave Medical (SWAV)?

衝擊波醫療(SWAV)的目標價是多少？

The latest price target for ShockWave Medical (NASDAQ: SWAV) was reported by Piper Sandler on January 26, 2023. The analyst firm set a price target for $280.00 expecting SWAV to rise to within 12 months (a possible 46.94% upside). 17 analyst firms have reported ratings in the last year.

派珀·桑德勒於2023年1月26日報道了衝擊波醫療(納斯達克：SWAV)的最新目標價。這家分析公司將目標價定為280.00美元，預計SWAV12個月內將升至46.94%。過去一年，17家分析公司公佈了評級。

What is the most recent analyst rating for ShockWave Medical (SWAV)?

Shockwave Medical(SWAV)的最新分析師評級是多少？

The latest analyst rating for ShockWave Medical (NASDAQ: SWAV) was provided by Piper Sandler, and ShockWave Medical maintained their overweight rating.

納斯達克(Sequoia Capital)的最新分析師評級由派珀·桑德勒提供，衝擊波醫療維持其增持評級。

When is the next analyst rating going to be posted or updated for ShockWave Medical (SWAV)?

Shockwave Medical(SWAV)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ShockWave Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ShockWave Medical was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Shockwave Medical的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Shockwave Medical的上一次評級是在2023年1月26日提交的，所以你應該預計下一次評級將在2024年1月26日左右的某個時候提供。

Is the Analyst Rating ShockWave Medical (SWAV) correct?

分析師對Shockwave Medical(SWAV)的評級正確嗎？

While ratings are subjective and will change, the latest ShockWave Medical (SWAV) rating was a maintained with a price target of $300.00 to $280.00. The current price ShockWave Medical (SWAV) is trading at is $190.55, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的衝擊波醫療評級維持不變，目標價在300.00美元至280.00美元之間。目前衝擊波醫療的交易價格為190.55美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論